Fny Investment Advisers, LLC Argenx Se Transaction History

Fny Investment Advisers, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 12, 2024	BUY	$338.91 - $506.01 $33,891 - $50,601	100 New	100 $38,000
Q1 2021 Apr 12, 2021	SELL	$268.3 - $380.31 $1.56 Million - $2.21 Million	-5,800 Closed	0 $0
Q4 2020 Jan 19, 2021	BUY	$248.13 - $308.36 $1.44 Million - $1.79 Million	5,800 New	5,800 $1.71 Million
Q3 2020 Oct 09, 2020	SELL	$215.51 - $272.51 $215,510 - $272,510	-1,000 Closed	0 $0
Q2 2020 Jul 10, 2020	BUY	$127.44 - $232.72 $127,440 - $232,720	1,000 New	1,000 $225,000
Q1 2020 Apr 09, 2020	SELL	$108.83 - $165.23 $721,651 - $1.1 Million	-6,631 Closed	0 $0
Q4 2019 Jan 10, 2020	BUY	$106.59 - $164.21 $123,218 - $189,826	1,156 Added 21.11%	6,631 $1.06 Million
Q3 2019 Oct 25, 2019	BUY	$113.31 - $150.51 $620,372 - $824,042	5,475 New	5,475 $623,000
Q2 2019 Jul 24, 2019	SELL	$115.0 - $141.58 $345,000 - $424,740	-3,000 Closed	0 $0
Q1 2019 Apr 17, 2019	BUY	$98.85 - $134.59 $296,550 - $403,770	3,000 New	3,000 $374,000
Q4 2018 Jan 22, 2019	SELL	$63.81 - $109.82 $2.74 Million - $4.72 Million	-43,000 Closed	0 $0
Q3 2018 Oct 29, 2018	BUY	$75.5 - $96.63 $3.25 Million - $4.16 Million	43,000 New	43,000 $3.26 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Fny Investment Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Fny Investment Advisers, LLC with notifications on news.